Published in Vaccine on September 28, 2004
Vaccines against gonorrhea: current status and future challenges. Vaccine (2013) 1.10
Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops. PLoS One (2009) 0.88
Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Crit Rev Microbiol (2016) 0.87
Positively selected codons in immune-exposed loops of the vaccine candidate OMP-P1 of Haemophilus influenzae. J Mol Evol (2007) 0.84
Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity. Clin Vaccine Immunol (2010) 0.82
A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. Vaccine (2013) 0.81
Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine. PLoS One (2012) 0.80
Mimetic membrane system to carry multiple antigenic proteins from Leishmania amazonensis. J Membr Biol (2006) 0.77
Mucosal Vaccine Development Based on Liposome Technology. J Immunol Res (2016) 0.75
Current prospects and future challenges for nasal vaccine delivery. Hum Vaccin Immunother (2016) 0.75
Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet (2003) 7.91
Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res (2010) 3.40
Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res (2008) 2.63
Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem (2003) 2.60
Structure-immunogenicity relationships of therapeutic proteins. Pharm Res (2004) 2.39
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol (2007) 2.31
Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol (2006) 1.98
Antibiotic guidelines and antibiotic use in adult bacterial meningitis in The Netherlands. J Antimicrob Chemother (2002) 1.90
Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release (2009) 1.81
Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med (2002) 1.73
Contribution of fibronectin-binding protein to pathogenesis of Streptococcus suis serotype 2. Infect Immun (2002) 1.69
Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis (2009) 1.65
A Neisserial autotransporter NalP modulating the processing of other autotransporters. Mol Microbiol (2003) 1.56
Characterization of genetic and phenotypic diversity of invasive nontypeable Haemophilus influenzae. Infect Immun (2005) 1.53
Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release (2012) 1.49
Quality of original and biosimilar epoetin products. Pharm Res (2010) 1.46
Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug Chem (2006) 1.37
Detection of a point mutation associated with high-level isoniazid resistance in Mycobacterium tuberculosis by using real-time PCR technology with 3'-minor groove binder-DNA probes. J Clin Microbiol (2003) 1.37
Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res (2010) 1.35
Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity? Pharm Res (2003) 1.34
Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci (2006) 1.32
Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res (2005) 1.32
Use of multilocus variable-number tandem-repeat analysis for typing Mycobacterium avium subsp. paratuberculosis. J Clin Microbiol (2004) 1.31
Mycobacterium microti infection (vole tuberculosis) in wild rodent populations. J Clin Microbiol (2002) 1.30
Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev (2009) 1.26
Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One (2011) 1.25
Adjuvant effect of cationic liposomes and CpG depends on administration route. J Control Release (2011) 1.24
The Omp85 protein of Neisseria meningitidis is required for lipid export to the outer membrane. EMBO J (2003) 1.23
Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci (2009) 1.23
Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci (2009) 1.23
Dissemination of lipid A deacylases (pagL) among gram-negative bacteria: identification of active-site histidine and serine residues. J Biol Chem (2004) 1.22
Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res (2011) 1.22
Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA (2010) 1.21
Cognitive impairment in adults with good recovery after bacterial meningitis. J Infect Dis (2002) 1.20
Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release (2010) 1.20
A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem (2006) 1.19
Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res (2008) 1.19
Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis. Infect Immun (2008) 1.16
Forced degradation of therapeutic proteins. J Pharm Sci (2011) 1.16
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci (2010) 1.16
Crystal structure and catalytic mechanism of the LPS 3-O-deacylase PagL from Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2006) 1.15
Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands. J Clin Microbiol (2002) 1.15
Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release (2010) 1.13
Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release (2005) 1.13
Roles of interleukin-6 and macrophage inflammatory protein-2 in pneumolysin-induced lung inflammation in mice. J Infect Dis (2001) 1.11
Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine (2010) 1.09
Group a streptococcal meningitis in adults: report of 41 cases and a review of the literature. Clin Infect Dis (2002) 1.09
Naturally occurring lipid A mutants in neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy. PLoS Pathog (2009) 1.08
Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cell Microbiol (2006) 1.08
T cell memory response to pneumococcal protein antigens in an area of high pneumococcal carriage and disease. J Infect Dis (2009) 1.08
Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect Immun (2006) 1.07
Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res (2010) 1.05
Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci U S A (2005) 1.03
Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release (2012) 1.03
Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine (2004) 1.03
Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem (2002) 1.02
Self-assembly of recombinant amphiphilic oligopeptides into vesicles. Biomacromolecules (2007) 1.02
Sensitive spectroscopic detection of large and denatured protein aggregates in solution by use of the fluorescent dye Nile red. J Fluoresc (2007) 1.02
Rational design of nasal vaccines. J Drug Target (2008) 1.02
Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm (2003) 1.02
Acquisition of pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-tract mucosal lymphoid tissue. PLoS Pathog (2011) 1.02
Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine (2006) 1.01
Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV infection. J Infect Dis (2011) 1.01
Impaired CD4 T cell memory response to Streptococcus pneumoniae precedes CD4 T cell depletion in HIV-infected Malawian adults. PLoS One (2011) 1.00
Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region. Vaccine (2006) 1.00
Defective pneumococcal-specific Th1 responses in HIV-infected adults precedes a loss of control of pneumococcal colonization. Clin Infect Dis (2012) 1.00
Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J Infect Dis (2004) 1.00
Human dendritic cell activation by Neisseria meningitidis: phagocytosis depends on expression of lipooligosaccharide (LOS) by the bacteria and is required for optimal cytokine production. Cell Microbiol (2004) 0.99
Erythropoietin-Associated PRCA: Still an Unsolved Mystery. J Immunotoxicol (2006) 0.99
Mucosal immunity in resource-limited setting: is the battle ground different? Trends Microbiol (2010) 0.98
Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. MAbs (2012) 0.98
Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments. AAPS J (2013) 0.98
Detection of imported malaria with the Cell-Dyn 4000 hematology analyzer. J Clin Microbiol (2002) 0.98
Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation. Anal Biochem (2008) 0.97
A novel phase-variable autotransporter serine protease, AusI, of Neisseria meningitidis. Microbes Infect (2006) 0.97
Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography. Pharm Res (2010) 0.97
Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J Control Release (2010) 0.97
Expression of foreign LpxA acyltransferases in Neisseria meningitidis results in modified lipid A with reduced toxicity and retained adjuvant activity. Cell Microbiol (2002) 0.97
Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res (2011) 0.97
Do multiple concurrent infections in African children cause irreversible immunological damage? Immunology (2012) 0.96
Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheum (2002) 0.96
Mapping the binding domains on meningococcal Opa proteins for CEACAM1 and CEA receptors. Mol Microbiol (2003) 0.96
Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis. J Immunol (2003) 0.96
Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun (2007) 0.96
Probing metal ion binding and conformational properties of the colicin E9 endonuclease by electrospray ionization time-of-flight mass spectrometry. Protein Sci (2002) 0.96
A novel secondary acyl chain in the lipopolysaccharide of Bordetella pertussis required for efficient infection of human macrophages. J Biol Chem (2007) 0.95
Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J Endotoxin Res (2004) 0.95